Skip to main content

SMARCA4-deficient Malignant Tumors clinical trials at UCSF

1 research study open to eligible people

SMARCA4-deficient malignant tumors are cancers missing a key gene that helps control cell growth. UCSF is studying how two immunotherapy drugs, nivolumab and ipilimumab, might treat these tumors in children and young adults. These trials aim to find new ways to manage these challenging cancers.

Showing trials for

Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include .

Last updated: